PSUSA/00002204/202404

Human medicines European public assessment report (EPAR): Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma), dabigatran etexilate, Date of authorisation: 19/02/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Cablivi, caplacizumab, Date of authorisation: 30/08/2018, Revision: 9, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Prevexxion RN+HVT+IBD, Infectious bursal disease and Marek's disease vaccine (live recombinant), Status: Authorised

Veterinary medicines European public assessment report (EPAR): Metacam, meloxicam, Status: Authorised

Human medicines European public assessment report (EPAR): Sancuso, granisetron, Date of authorisation: 20/04/2012, Revision: 15, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Frontpro (previously Afoxolaner Merial), afoxolaner, Date of authorisation: 20/05/2019, Status: Authorised

Human medicines European public assessment report (EPAR): Cerezyme, imiglucerase, Date of authorisation: 17/11/1997, Revision: 33, Status: Authorised

Committee for Advanced Therapies (CAT): 4-6 December 2024, European Medicines Agency, Amsterdam, the Netherlands, from 4 December 2024 to 6 December 2024

Agenda of the CAT meeting 4-6 December 2024